Get the Stockscreener App
205.29
1.27%
2.57
After Hours:
204.00
-1.29
-0.63%
Overview
News
Price History
Option Chain
Financials
Why ABBV Down?
Discussions
Forecast
Dividend History
Abbvie Inc stock is traded at $205.29, with a volume of 6.48M.
It is up +1.27% in the last 24 hours and up +0.13% over the past month.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics (including Botox).
See More
Previous Close:
$202.72
Open:
$202.73
24h Volume:
6.48M
Relative Volume:
1.15
Market Cap:
$363.15B
Revenue:
$56.33B
Net Income/Loss:
$4.28B
P/E Ratio:
85.54
EPS:
2.4
Net Cash Flow:
$17.83B
1W Performance:
-2.25%
1M Performance:
+0.13%
6M Performance:
+5.39%
1Y Performance:
+12.73%
1-Day Range:
$201.59
$206.02
1-Week Range:
$196.49
$211.02
52-Week Range:
$153.58
$218.66
Abbvie Inc Stock (ABBV) Company Profile
Name
Abbvie Inc
Sector
Industry
Phone
(847) 932-7900
Address
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
205.29 | 363.15B | 56.33B | 4.28B | 17.83B | 2.40 |
|
LLY
Lilly Eli Co
|
822.51 | 738.75B | 45.04B | 10.59B | 414.30M | 11.71 |
|
JNJ
Johnson Johnson
|
163.71 | 344.63B | 88.82B | 14.07B | 18.06B | 5.79 |
|
NVO
Novo Nordisk Adr
|
69.30 | 311.44B | 42.09B | 14.65B | 10.11B | 3.2833 |
|
MRK
Merck Co Inc
|
89.23 | 225.40B | 64.17B | 17.12B | 18.10B | 6.73 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Dec-05-24 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Nov-22-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Nov-04-24 | Upgrade | Argus | Hold → Buy |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Jun-05-24 | Upgrade | HSBC Securities | Hold → Buy |
| May-17-24 | Initiated | Cantor Fitzgerald | Overweight |
| Jan-29-24 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-18-23 | Downgrade | HSBC Securities | Buy → Hold |
| Dec-11-23 | Upgrade | Goldman | Neutral → Buy |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-30-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Oct-20-23 | Resumed | UBS | Neutral |
| Sep-29-23 | Initiated | Raymond James | Outperform |
| Jul-25-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-05-23 | Downgrade | Argus | Buy → Hold |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-22-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Feb-10-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Nov-08-22 | Downgrade | Societe Generale | Buy → Hold |
| Aug-01-22 | Downgrade | Atlantic Equities | Overweight → Neutral |
| May-23-22 | Initiated | SVB Leerink | Underperform |
| May-06-22 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Feb-28-22 | Downgrade | UBS | Buy → Neutral |
| Feb-03-22 | Reiterated | BMO Capital Markets | Outperform |
| Feb-03-22 | Reiterated | Barclays | Equal Weight |
| Feb-03-22 | Reiterated | BofA Securities | Neutral |
| Feb-03-22 | Reiterated | Goldman | Neutral |
| Jan-13-22 | Initiated | Redburn | Buy |
| Jan-12-22 | Reiterated | BMO Capital Markets | Outperform |
| Dec-09-21 | Resumed | Wells Fargo | Overweight |
| Nov-23-21 | Upgrade | Societe Generale | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Nov-10-20 | Resumed | Bernstein | Outperform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-23-20 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Jun-09-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Jun-02-20 | Upgrade | Argus | Hold → Buy |
| May-18-20 | Resumed | BofA/Merrill | Neutral |
| May-12-20 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-20 | Resumed | Morgan Stanley | Overweight |
| Apr-20-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-23-20 | Downgrade | Societe Generale | Buy → Hold |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Dec-26-19 | Reiterated | Cowen | Outperform |
| Sep-26-19 | Upgrade | Citigroup | Neutral → Buy |
| Aug-20-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Jun-27-19 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| Jun-26-19 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| May-28-19 | Initiated | Goldman | Neutral |
| Apr-29-19 | Upgrade | BMO Capital Markets | Underperform → Market Perform |
View All
Abbvie Inc Stock (ABBV) Latest News
AbbVie Inc. (ABBV): Among the Best Dividend Aristocrat Stocks with Over 3% Yield - Insider Monkey
Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra - ACCESS Newswire
AbbVie Vs. Sanofi: Which Is The Better Investment Right Now (NYSE:ABBV) - Seeking Alpha
AbbVie (ABBV) Rebounds After Consecutive Losses, Eyes Future Gro - GuruFocus.com
Regencell, GlucoTrack, TC Biopharm, AbbVie, Actinium: 5 Health Care Stocks That Lit Up Retail Discussions Last Week - MSN
AbbVie shares rose after seven consecutive sessions of losses (NYSE:ABBV) - Seeking Alpha
Corticosteroids Market May See a Big Move | Major Giants- AbbVie, Astellas Pharma, AstraZeneca - openPR
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
AbbVie (NYSE:ABBV) Showcases Oncology Innovations Amidst 6% Share Price Dip - Yahoo Finance
Non-Small Cell Lung Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics, AstraZeneca - Barchart
AbbVie Showcases Early Pipeline and Scientific Advances in Oncology at AACR Annual Meeting 2025 - PR Newswire
2 Dividend Stocks Defying the Market Dip to Buy for a Lifetime of Passive Income - Yahoo Finance
AbbVie Stock Boosts Portfolios With Entry Into Weight Loss Market - MSN
AbbVie accuses oncology partner of stealing trade secrets - Crain's Chicago Business
AbbVie Inc (ABBV) Shares Gap Down to $202.37 on Mar 25 - GuruFocus.com
Smart Money Is Betting Big In ABBV OptionsAbbVie (NYSE:ABBV) - Benzinga
AbbVie sues Genmab, claiming trade secrets theft - pharmaphorum
AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Abbvie CEO Robert A. Michael's 2024 Total Compensation Was $18.5 MillionFiling -March 24, 2025 at 04:44 pm EDT - Marketscreener.com
AbbVie lawsuit alleges that partner Genmab “misappropriated” trade secrets - PharmaLive
Genmab stock falls amid AbbVie lawsuit By Investing.com - Investing.com South Africa
Genmab to Defend Against AbbVie’s Trade Secret Misappropriation Claims - TipRanks
Genmab stock falls amid AbbVie lawsuit - Investing.com
AbbVie Lawsuit Alleges That Partner Genmab "Misappropriated” Trade Secrets - BioSpace
Genmab faces trade secret claims by AbbVie - Investing.com India
Genmab Denies Trade Secret Misappropriation Claims by AbbVie -March 24, 2025 at 08:21 am EDT - Marketscreener.com
Allergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025 - AbbVie
Genmab dismisses Abbvie lawsuitaccused of exploiting trade secrets -March 24, 2025 at 03:30 am EDT - Marketscreener.com
Global Autoimmune Disease Therapeutics Market to reach USD 226,194.0 Million by 2035 Amid Rising Prevalence and Advancements in Biologic Therapies | Future Market Insights, Inc. - GlobeNewswire Inc.
Is AbbVie Inc. (ABBV) The Best Healthcare Dividend Stock to Invest in? - Insider Monkey
Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc. - GlobeNewswire
Genmab To Vigorously Defend Alleged Claims Of Trade Secret Misappropriation By Abbvie Inc. - Marketscreener.com
Is AbbVie Gaining or Losing Market Support?AbbVie (NYSE:ABBV) - Benzinga
Non-Small Cell Lung Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | AbbVie, Xcovery, Sanofi, Pfizer, Mirati Therapeutics, AstraZeneca, Daiichi Sankyo - Barchart
Open Angle Glaucoma Market to Show Remarkable Growth Trends from 2023 to 2032, DelveInsight Reports | Visiox Pharma, TearClear, VivaVision Biotech, Inc., Abbvie, Ocuphire Pharma, Qlaris Bio, Inc - The Globe and Mail
Botox Market Demand, Growth, Demand and Future Scope 2025-2032 | - openPR
AbbVie wins FDA nod for infusion treatment for advanced Parkinson’s disease - MSN
AbbVie Options Trading: A Deep Dive into Market Sentiment - Benzinga
Advancing Oncology: Innovations in Treatment and Detection - Value the Markets
Parkinson’s Disease Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis | AbbVie, Pfizer, Novartis, F. Roche, Kissei Pharma, AstraZeneca, Prevail Therapeutics, Amnea - Barchart
Alzheimers Drugs Market Is Booming Worldwide | AbbVie, Inc., Teva Pharmaceuticals Ltd., Eisai Co., Ltd - openPR
Abbvie Inc. (ABBV) Elliott Wave technical analysis [Video] - FXStreet
Immunology Drugs Market Key Players AnalysisEli Lilly, AbbVie Inc, F.Hoffmann-La roche Ltd, Amgen Inc, Pfizer. - openPR
Transitional Cell Carcinoma Treatment Market Size in 7MM - openPR
AbbVie (ABBV) Stock Moves -0.29%: What You Should Know - Yahoo Finance
AbbVie CFO Scott Reents sells $3.75 million in stock By Investing.com - Investing.com Australia
AbbVie CFO Scott Reents sells $3.75 million in stock - Investing.com
Endometriosis Pain Pipeline 2025: FDA Approvals and Clinical - openPR
Widely used drugs on US imports list from Europe - Reuters.com
AbbVie upgraded to Buy at Erste Group on Friday - Yahoo Finance
AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients - Benzinga India
Abbvie Inc Stock (ABBV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
1.23%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):